GLP-1 Cost Without Insurance 2026: Every Legitimate Cash-Pay Path
Roughly 35 million Americans don't have insurance that covers GLP-1s, and another 20 million have insurance that's denied prior authorization for them. The cash-pay question is the single biggest GLP-1 access conversation in 2026, and the honest answer is more interesting than “it's expensive.”
Real cash-pay options in 2026 range from $179/month (compounded semaglutide via licensed pharmacies) to $399/month (LillyDirect Zepbound vials) to $499/month (NovoCare Wegovy and Ozempic) to $1,349/month (retail Wegovy). The 7× spread between the cheapest and most expensive paths is real — and the cheapest path is genuinely legitimate when you do the pharmacy verification work.
Every cash-pay path in 2026, ranked by cost
| Path | What it is | Monthly cost | Best for |
|---|---|---|---|
| Compounded semaglutide | Same molecule as Ozempic/Wegovy, prepared at a state-licensed 503A or 503B pharmacy | $179–$349 | Cash-pay shoppers comfortable with post-shortage compounding rules |
| Compounded tirzepatide | Same molecule as Mounjaro/Zepbound, prepared at a state-licensed pharmacy | $249–$499 | Cash-pay shoppers wanting tirzepatide |
| LillyDirect Self Pay | Eli Lilly's direct cash channel for Zepbound single-dose vials | $399–$549 | Cash-pay shoppers who want brand-name Zepbound |
| NovoCare Pharmacy | Novo Nordisk's direct cash channel for Wegovy and Ozempic | $499 | Cash-pay shoppers who want brand-name Wegovy or Ozempic |
| Patient assistance programs | Income-based programs from Novo Nordisk and Eli Lilly | $0–$25 | Uninsured patients under 400% of federal poverty level |
| Costco / warehouse pharmacy | Discounted retail at member pharmacies | ~$800–$1,100 | Patients without access to direct manufacturer programs |
| Standard retail | CVS, Walgreens, etc. without discount card | $998–$1,349 | Nobody — never pay this price; alternatives always exist |
Why compounded GLP-1 is dramatically cheaper
Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredient (API) as the branded drugs. The price difference reflects the absence of three things: marketing budget, patent royalties, and the FDA-approved end-product manufacturing pipeline. Compounded preparations are made in smaller batches at state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities against individual prescriptions.
In 2026, the legal landscape is narrower than it was in 2024. The FDA declared semaglutide off the shortage list in early 2025 and tirzepatide off in late 2024, ending the broad mass-prep window that drove the 2023–2024 boom. What remains legal: individual clinically-justified prescriptions prepared at properly licensed pharmacies. Reputable telehealth programs (Henry Meds, Mochi Health, Eden, others) adapted their workflows; less reputable ones disappeared.
The verification work matters. Reputable compounded programs name their pharmacy partner, disclose the state license number, and provide third-party testing certificates on request. Programs that won't disclose their pharmacy partner are worth avoiding regardless of price.
The 7× spread between the cheapest legitimate cash path ($179 compounded) and standard retail ($1,349 Wegovy) is real. Most patients pay closer to the bottom because the bottom is genuinely accessible.
Manufacturer cash channels: NovoCare and LillyDirect
Both major GLP-1 manufacturers run direct-to-patient cash channels that significantly undercut retail. NovoCare Pharmacyships brand-name Wegovy and Ozempic at $499/month for cash-pay patients without insurance coverage. The product is identical to retail; the price reflects Novo Nordisk's strategic decision to capture cash-pay patients rather than lose them to compounded alternatives.
LillyDirect Self Pay, launched in 2024, sells Zepbound single-dose vials at $399–$549/month. The vials require drawing up syringes manually (a $5–$10 weekly supply expense), but the per-month cost is meaningfully lower than NovoCare's. Mounjaro is not available through LillyDirect — that channel is specifically for the weight-management product.
Both manufacturers also run separate patient assistance programs for uninsured patients below 400% of federal poverty level. These can drop monthly cost to $0 for qualifying patients but require income documentation and have stricter eligibility criteria than the standard cash channels.
What to skip: programs that aren't worth the price
Standard retail pharmacy cash prices ($998–$1,349/month) should never be your default — alternatives always exist. Programs that hide post-trial pricing on the first checkout screen are red flags (FTC issued enforcement guidance for negative-option marketing in this category in 2025). International pharmacy imports carry counterfeit risk and federal compliance issues that aren't worth the price gap.
Programs charging high membership fees ($295+/month) on top of a low “medication fee” often cost more than NovoCare or LillyDirect once you sum the line items. Calculate the all-in monthly cost before comparing.
GLP-1 cost FAQ
What is the cheapest GLP-1 without insurance?
Compounded semaglutide is typically the cheapest legitimate path at $179–$249/month for the first month and $249–$349/month ongoing. The brand-name cash-pay options bottom out at $399/month (LillyDirect Zepbound vials) and $499/month (NovoCare Wegovy or Ozempic).
Is compounded semaglutide really 60% cheaper than Wegovy?
Roughly. NovoCare cash Wegovy is $499/month. Compounded semaglutide ranges $179–$349/month all-in (including telehealth consult, medication, supplies). The compounded preparation uses the same active ingredient but isn't FDA-reviewed as a specific end product.
Can I use HSA or FSA to pay for GLP-1s?
Yes for branded products with a prescription. Compounded preparations are sometimes reimbursable depending on plan administrator policy — verify before assuming coverage. Save all receipts and prescription documentation.
What's NovoCare Pharmacy?
Novo Nordisk's direct-to-patient cash-pay channel. NovoCare ships brand-name Wegovy and Ozempic at $499/month for patients without insurance coverage of the drug. It's not a free program — it's a discounted cash-pay rate, roughly half of retail.
What's LillyDirect Self Pay?
Eli Lilly's direct cash-pay channel for Zepbound. Sells single-dose vials at $399–$549/month depending on dose. The vials require manual dosing (drawing up syringes) rather than the pre-filled pen, but the price is the lowest brand-name cash option for tirzepatide.
Are there patient assistance programs for GLP-1s?
Yes. Both Novo Nordisk and Eli Lilly run income-based patient assistance programs for uninsured patients who meet specific income criteria (typically <400% of federal poverty level). Documentation requirements are stricter than the savings cards but discounts can go to $0 for qualifying patients.
Can I get GLP-1s from a Mexican or Canadian pharmacy?
Importing prescription drugs from outside the U.S. for personal use is technically illegal under federal law (FDA enforcement is selective). Risks include counterfeit products, customs seizure, and no recourse for quality issues. We don't recommend this path — domestic compounded programs are typically cheaper and legally cleaner.
How much does the telehealth consult cost?
Cash-pay telehealth consults for GLP-1s typically run $32–$99 for the initial intake and either a flat monthly membership fee ($99–$295) or per-visit fees ($49–$99) for ongoing care. The total cost should be visible at checkout — programs that hide post-trial pricing are red flags.
Will Costco or warehouse pharmacies discount GLP-1s?
Costco and similar warehouse pharmacies can shave 10–20% off retail GLP-1 prices for cash-pay patients vs. major chains, but they don't approach the cash-pay levels of NovoCare, LillyDirect, or compounded programs. Worth checking, but not the primary path.
Can my doctor give me free GLP-1 samples?
Sometimes — Novo Nordisk and Eli Lilly distribute physical sample pens to prescribing clinicians (not patients), typically the lowest titration dose. Ask your prescribing clinician directly. Sample availability is unpredictable and clinician-discretionary.